Sertraline Dosing Guidelines
Start sertraline at 50 mg once daily for major depressive disorder and OCD in adults, but use 25 mg once daily for panic disorder, PTSD, and social anxiety disorder to minimize early activation symptoms. 1
Adult Dosing by Indication
Major Depressive Disorder and OCD
- Starting dose: 50 mg once daily 1
- Titration: Increase in 50 mg increments at intervals of at least 1 week based on response 1
- Effective range: 50–200 mg/day 1
- Maximum dose: 200 mg/day 1
Panic Disorder, PTSD, and Social Anxiety Disorder
- Starting dose: 25 mg once daily 1
- After 1 week: Increase to 50 mg once daily 1
- Titration: Increase in 50 mg increments at intervals of at least 1 week if needed 1
- Effective range: 50–200 mg/day 1
- Maximum dose: 200 mg/day 1
The lower starting dose for anxiety disorders reduces the risk of early behavioral activation, agitation, and anxiety that can occur with SSRIs, particularly in panic disorder and PTSD. 2
Premenstrual Dysphoric Disorder
- Starting dose: 50 mg/day 1
- Dosing schedule: Either daily throughout the menstrual cycle OR limited to luteal phase only 1
- Titration: Increase in 50 mg increments at the onset of each new menstrual cycle 1
- Maximum dose: 150 mg/day (continuous dosing) or 100 mg/day (luteal phase only) 1
- Luteal phase initiation: Use 50 mg/day titration step for 3 days at the beginning of each luteal phase dosing period if established on 100 mg/day 1
Pediatric and Adolescent Dosing
Obsessive-Compulsive Disorder (FDA-Approved)
Children (ages 6–12):
- Starting dose: 25 mg once daily 1
- Titration: Increase up to 200 mg/day based on response 1
- Maximum dose: 200 mg/day 1
Adolescents (ages 13–17):
- Starting dose: 50 mg once daily 1
- Titration: Increase up to 200 mg/day based on response 1
- Maximum dose: 200 mg/day 1
Sertraline is the only SSRI with FDA approval for pediatric OCD (ages 6–17). 2 Dose changes should occur at intervals of at least 1 week given sertraline's 24-hour elimination half-life. 1
Major Depressive Disorder (Off-Label in Adolescents)
- Starting dose: 25 mg once daily 3
- Titration: Increase in 12.5–25 mg increments as tolerated 3
- Effective dose: 50 mg/day 3
- Maximum dose: 200 mg/day 3
Critical safety consideration: Starting at doses higher than recommended increases the risk of deliberate self-harm and suicidal behavior in adolescents. 2 Close monitoring is mandatory during the first few months of treatment and after each dose adjustment. 3, 2
Important Pharmacokinetic Consideration in Adolescents
At low doses (50 mg/day), many adolescents may require twice-daily dosing because the steady-state half-life becomes significantly shorter (15.3 hours) compared to single-dose half-life (26.7 hours). 4 At higher doses (100–150 mg/day), the half-life increases to 20.4 hours, making once-daily dosing more appropriate. 4 Additionally, at low doses of sertraline and at any dose of fluvoxamine, youths may require twice-daily dosing. 5
Geriatric Dosing
No dose reduction is required solely based on age. 2, 6
- Starting dose: Same as adults (50 mg/day for depression/OCD; 25 mg/day for anxiety disorders) 1, 6
- Maximum dose: 200 mg/day 2, 6
- Dosing frequency: Once daily 1
Sertraline has a distinct advantage in elderly patients because it does not require age-based dose adjustments, unlike some other SSRIs. 6, 7 The drug is generally well tolerated in this population and lacks the marked anticholinergic effects of tricyclic antidepressants. 6
Special monitoring in elderly patients: Watch for hyponatremia and fall risk, which are more common adverse events in patients ≥65 years. 8
Timing and Administration
- Frequency: Once daily, either morning or evening 1
- With or without food: Can be taken either way 1
- Exception for low doses: At 50 mg/day in adolescents or at any dose of fluvoxamine in youth, consider twice-daily dosing due to shorter half-life. 5, 4
Titration Principles
- Minimum interval between dose changes: 1 week, based on sertraline's 24-hour elimination half-life 1
- Optimal titration strategy: Slow up-titration to avoid exceeding the optimal dose, as clinical improvement follows a logarithmic pattern with maximal benefit by week 12 or later 5
- Response timeline: Statistically significant improvement may occur within 2 weeks, but clinically significant improvement typically requires 6 weeks, with maximal response by week 12 5
Maintenance Treatment Duration
Major Depressive Disorder
- First episode: Continue for 4–9 months after satisfactory response 9, 1
- Two or more episodes: Longer duration of therapy is beneficial 9
- Evidence base: Efficacy maintained for up to 44 weeks in controlled trials 1
PTSD
- Continue for at least 28 weeks following initial 24-week treatment response 1
Social Anxiety Disorder
- Continue for at least 24 weeks following initial 20-week treatment response 1
OCD and Panic Disorder
- Require several months or longer of sustained therapy beyond initial response 1
Discontinuation Strategy
Always taper sertraline gradually over 10–14 days rather than stopping abruptly. 2
Sertraline can cause discontinuation syndrome, though its incidence and severity are lower than with paroxetine. 2 Common withdrawal symptoms include dizziness, fatigue, nausea, insomnia, sensory disturbances, and anxiety. 2 All SSRIs should be slowly tapered when discontinued because of risk of withdrawal effects. 3
Critical Drug Interactions
- Absolute contraindication: Monoamine oxidase inhibitors (MAOIs) due to serotonin syndrome risk 3, 2, 1
- Bile-acid sequestrants: Administer sertraline at least 4 hours apart to avoid binding and reduced absorption 2
- CYP2D6 substrates: Sertraline may inhibit CYP2D6, requiring caution with drugs metabolized by this pathway 2
- Aspirin/NSAIDs: Increased risk of abnormal bleeding when combined with sertraline 5
Sertraline has a lower potential for drug-drug interactions compared to other SSRIs, making it particularly advantageous in elderly patients who often take multiple medications. 2, 6, 7
Monitoring Requirements
Initial Phase (First 1–2 Weeks)
- Assess patient status, therapeutic response, and adverse effects regularly 9
- Monitor closely for suicidality, especially in patients under age 24 3, 5
- Watch for behavioral activation/agitation (motor restlessness, insomnia, impulsiveness, disinhibited behavior), which is more common in younger children and anxiety disorders 5
Ongoing Monitoring
- If no adequate response within 6–8 weeks, modify treatment 9
- Continue monitoring for suicidality during the first months and after dose adjustments 5
- In pediatric patients on long-term treatment, monitor weight and growth regularly 1
Adolescent-Specific Monitoring
The FDA black-box warning mandates close observation for clinical worsening, suicidality, and unusual behavioral changes, especially during initial months and after dose changes. 3 The pooled risk difference for suicidal ideation is 0.7% (NNH = 143), compared to NNT = 3 for achieving response. 5 Telephone follow-up can be as effective as in-person visits for detecting adverse events. 2
Common Adverse Effects
Most adverse effects emerge within the first few weeks and include: 5
- Gastrointestinal: nausea, diarrhea, dry mouth, constipation
- Neurological: headache, dizziness, tremor
- Sleep-related: insomnia, somnolence
- Other: sweating, changes in appetite, weight changes, sexual dysfunction
Newly identified adverse reactions requiring vigilance: genital anesthesia, bruxism, and microscopic colitis 8
Special Clinical Situations
Renal Impairment
No dose adjustment required 1
Hepatic Impairment
Use with caution; consider lower doses or less frequent dosing (not explicitly detailed in FDA label) 1
Pregnancy and Nursing
Carefully weigh risks versus benefits; sertraline and metabolites may be excreted in breast milk 1